Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Brian Quigley Insider Profile
4 Followers
Brian Quigley, Director at MustGrow Biologics, holds 399.00K shares in MustGrow Biologics (Ticker: MGROF). Most recently, Brian Quigley Sold $40,000 shares of MustGrow Biologics on Dec 08, 2022 for an estimated value of 134.42K.
Profitable Transactions
2 out of 2 Profitable Transactions
Average Return
+67.40%
Average return per transaction
Time Frame
Compare to
Insider Roles
Director
Roles that Brian Quigley holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Dec 08, 2022 - Dec 08, 2023
Return:+68.30%
The most profitable trade made by Brian Quigley
Brian Quigley's Trading History
List of latest transactions for each holding click on a transaction to see Brian Quigley's performance on stock
You May Also Like
Brian Quigley insider profile FAQ
What is the percentage of profitable transactions made by Brian Quigley?
The percentage of profitable transactions made by Brian Quigley is 100%.
What is the average return per transaction made by Brian Quigley?
The average return per transaction made by Brian Quigley is 67.40%.
What stocks does Brian Quigley hold?
Brian Quigley holds: MGROF stocks.
What was Brian Quigley’s latest transaction?
Brian Quigley latest transaction was an Informative Sell of $134.42K.
What was Brian Quigley's most profitable transaction?
Brian Quigley’s most profitable transaction was an Informative Sell of MGROF stock on December 8, 2022. The return on the trade was 68.30%.
What is Brian Quigley's role in MustGrow Biologics?
Brian Quigley's role in MustGrow Biologics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.